Discover comprehensive details about Toremifene, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy MEMPHIS, Tenn. -- GTx today announced Phase III ...

Review the side-effects of Toremifene as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today announced that the company and Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of ...

Association of ADT for older men with biochemical recurrence of prostate cancer with obese frailty and falls: A case-control study. Initial feasibility and safety results from a phase II/III clinical ...

The selective estrogen-receptor (ER) modulator toremifene can either stimulate or block ERs in target tissues. In the prostate, toremifene blocks ERs, and is under evaluation as a chemopreventive ...

March 6, 2008 — Toremifene has been shown to reduce the incidence of vertebral fractures and hot flashes in men with prostate cancer taking androgen-deprivation therapy (ADT) in a phase 3 clinical ...

A Phase III study with GTx and Ipsen’s toremifene 20 mg failed to meet its primary endpoint of significantly reducing the incidence of prostate cancer in men with high-grade prostatic intraepithelial ...

GTx Incorporated announced top line results of its Phase 3 trial evaluating toremifene 20mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a ...

Study relates to the reduction of fractures in advanced prostate cancer patients on androgen-deprivation treatment. GTx could earn another €42 million (about $56.89 million) in milestone payments from ...

Figure 1: Summary of thermal-shift assays. Our results pinpoint the binding site of toremifene and ibuprofen on the surface of the GP and reveal that they decrease the stability of the viral GP, and ...